HHS Launched AI Program to Accelerate Clinical Trials

The federal SURPASS program aims to cut trial timelines by using AI to simulate research designs and scale data collection.

Updated on Oct. 5, 2026 in Artificial Intelligence

Isometric editorial illustration of a complex, interconnected research-module lattice structure, representing an AI-driven medical data pipeline. — The Department of Health and Human Services has launched the SURPASS program, an AI-driven initiative designed to automate clinical trial infrastructure and accelerate medical research timelines. AI Illustration. Upload story photo >

Live Poll

Do you trust that using artificial intelligence in clinical drug trials will improve patient safety?

The Department of Health and Human Services announced the SURPASS program and three associated projects designed to modernize clinical trial infrastructure. The effort utilizes artificial intelligence to manage patient data and trial simulation, seeking to lower costs and reduce research failures.

Why it matters

Clinical drug development faces a 90% failure rate and average costs of $2 billion per candidate. By applying AI to simulate trial outcomes and automate site activation, this initiative seeks to improve the efficiency of the national medical research pipeline.

The COMMONS initiative targets a database of 40 million individuals and 3 million linked records to streamline research. The program relies on a phaseless design engine to simulate outcomes, while the STACK project leverages AI to rapidly convert research-naïve facilities into active sites.

The players

Health and Human Services Department

The U.S. federal agency responsible for national public health, which oversees policy and funding for medical research infrastructure.

Evidence Health

A research entity serving as the prime awardee for the STACK and COMMONS initiatives to scale clinical site infrastructure.

Courage Health

A clinical research organization serving as the prime awardee for the CINCH project focused on patient-contributed trial data.

The details

The SURPASS program uses a phaseless design engine—a software platform that simulates patient responses to trial variables before human enrollment begins. The STACK initiative automates the technical and regulatory onboarding of new facilities to scale testing capacity. Meanwhile, the CINCH and COMMONS projects integrate large-scale health records to match eligible participants with research efforts more effectively.

April 2026: The FDA launched a pilot program using AI and cloud computing for clinical trial data.
June 2026: HHS announced Operation TrialBlazer.
October 6, 2026: HHS announced the SURPASS program and three associated projects.
November 30, 2026: The SURPASS solution summary is due.

The Tech Race

This program builds directly upon the groundwork laid by the FDA’s cloud-based AI pilot and Operation TrialBlazer. It represents a systematic effort to transition clinical research from manual, site-limited protocols to automated, simulation-heavy models.

For patients, the CINCH initiative creates a pathway to contribute personal health data to help identify relevant clinical trials. The program seeks to increase the number of active research sites, potentially making experimental treatments more accessible outside of major academic centers.

The takeaway

This initiative represents a pivot toward automated, data-centric drug development aimed at lowering the massive capital requirements of modern research. Stakeholders should monitor the November 30, 2026, solution summary for technical specifications on the proposed phaseless design engine.